



PCT/GB2004/001383



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport

REC'D 17 MAY 2004  
South Wales  
NP10 3PQ

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *Andrew George*  
Dated 7 May 2004

BEST AVAILABLE COPY

PRIORITY DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

## Patents Form 1/77

Patent No. 1977  
(Rule 10)25MARS03 E794837-1 000107  
P01/7700 000-0306782.41  
1/77

## Request for grant of a patent

*(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)*

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## 1. Your reference

TC / JR-MP100397-GB

## 2. Patent application number

*(The Patent Office will fill in this part)*

0306782.4

25 MAR 2003

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

NeuTec Pharma Plc  
Clinical Sciences Building  
Central Manchester Healthcare Trust  
Oxford Road  
Manchester M13 9WL  
UK

Patents ADP number (*if you know it*)

7254766001

UK

UK

## 4. Title of the invention

Treatment of Infection Due  
To Clostridium difficile5. Name of your agent (*if you have one*)*"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)*

Lloyd Wise, McNeight & Lawrence  
Regent House, Heaton Lane  
Stockport, Cheshire SK4 1BS

Patents ADP number (*if you know it*)

08458275001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)Date of filing  
(*day / month / year*)

## 7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer Yes if:*

Yes

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d).*

### Treatment of Infection due to *Clostridium difficile*

*Clostridium difficile* is a gram-positive anaerobic bacterium, and is deemed a significant human pathogen causing a spectrum of diseases ranging from mild diarrhoea to fulminant pseudomembranous colitis (PMC) - collectively referred to as *C. difficile* antibiotic-associated diarrhoea (CDAD). CDAD is a common, iatrogenic, nosocomial disease associated with substantial morbidity and mortality, especially in the elderly. Two factors have been assigned main roles in the pathogenesis of CDAD - the suppression of the resident intestinal flora by the administration of antibiotics, and the production by the bacterium of two high molecular weight toxins, toxin A and toxin B.

The bacterium is endemic in hospitals, and studies have shown that approximately one third of patients receiving antibiotic treatment in acute-care medical wards were colonised by *C. difficile* while in hospital (Kyne, L., et al., 2002, Clin. Infect. Dis. 34(3), pp346-53, PMID: 11774082). Of these patients, over half went on to develop CDAD while the remainder were symptomless carriers. CDAD is a major factor in extension of patient hospital stay times, and estimates suggest that the cost of this disease in the US exceeds \$1.1 billion per year (Kyne, L., et al., Supra). Patients suffering from CDAD respond well to a treatment which includes a discontinuation of the inciting antibiotic and treatment with either of the antibiotics metronidazole and vancomycin. However, the use of e.g. vancomycin is one of last resort since it is associated with several problems. Not only may it cause nephrotoxicity, ototoxicity, bone marrow toxicity and the red man syndrome, but the problem with this treatment regime is that the CDAD often returns after successful treatment of the initial episode, and this reoccurrence represents a serious clinical problem. Additionally, there is evidence that *C. difficile* is becoming resistant to metronidazole and partially resistant to vancomycin, demonstrating the need for new alternatives in the treatment of CDAD.

Exotoxins A and B which are produced by pathogenic strains of the bacterium are cytotoxic, enterotoxic and proinflammatory, and are considered to be the main virulence factors of this non-invasive microorganism. However, not all infections with toxigenic strains result in disease, prompting the search for additional virulence factors. Bacterial surface expressed antigens represent candidate virulence factors, and are also considered important since such proteins likely mediate the essential functions such as adhesion to the epithelial layer of the gut in the first step of colonization or interaction with mediators of local immunity. In common with many other bacteria, *C. difficile* expresses a crystalline or paracrystalline surface layer (S-layer) on the outer cell surface. Such S-layers comprise proteins or glycoproteins forming a regularly arranged lattice on the external surface of the bacterium, and have previously been shown to be essential for the virulence of pathogens such as *Aeromonas salmonicida* and *Campylobacter fetus*. In contrast to most bacteria which comprise one S-layer, *C. difficile* is known to comprise two superimposed paracrystalline S-layers, each composed of a glycoprotein subunit which varies slightly in apparent molecular weight among different *C. difficile* strains. Most strains of *C. difficile* express two major S-layer proteins (SLPs), one of 32-38 kDa (low-MW SLP) and a second of 42-48 kDa (high-MW SLP). The low-MW SLP appears to be immunodominant and is the antigen most commonly recognised by patients suffering from CDAD, and is the only antigen recognised in EDTA extracts of bacteria by antisera raised in rabbits against whole *C. difficile* cells (Calabi, E. et al., 2001, Mol. Microbiol., 40(5) p1187-99, PMID: 11401722).

Other non-antibiotic based therapeutic regimes for the treatment/prevention of *C. difficile* infection are based upon passive immunization and vaccination. Passive immunization relies on the administration to a patient of toxin neutralising antibodies (as disclosed in WO 99/20304), or antibodies raised against the whole bacterium and the toxins (as disclosed in WO 96/07430). Vaccination treatment comprises administering to a patient either a nucleic acid sequence encoding an immunogenic fragment of the *C. difficile*

surface layer protein or variant or homologue thereof, or an equivalent polypeptide fragment (as disclosed in WO 02/062379).

The present inventors have discovered that the low-MW SLP masks a previously 5 unidentified bacterial protein of 36 kDa (as determined by SDS-PAGE and Western blotting of bacterial extracts probed with patient antisera). The fact that this protein is recognised by antibodies present within sera isolated from patients infected with *Clostridium difficile* potentially implicates the protein in the pathogenesis of CDAD. As such, this protein and epitopes thereof potentially offer a wide range of uses - they may be 10 used therapeutically as immunogens, for example as vaccines, or diagnostically to detect agents (e.g. antibodies) which bind specifically to them. They may also be used to produce neutralising agents, for example antibodies, which may be used both therapeutically and diagnostically, either on their own, or in combination e.g. with other antibodies used for passive immunization.

15

According to the present invention there is provided a *C. difficile* lactate dehydrogenase (LDH) comprising the amino acid sequence of SEQ ID NO: 2. Some variation may exist within the amino acid sequence in accordance with the inter-strain variation exhibited by *C. difficile*. For example, a protein according to the present invention may exhibit at least 20 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% identity with the amino acid sequence of SEQ ID NO: 2.

Sequence homology/identity is as determined using the BLAST2 program (Tatusova TA *et al.*, FEMS Microbiol Lett. 1999 May 15;174(2):247-50; PMID: 10339815) at the 25 National Center for Biotechnology Information, USA ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) with default parameters. As used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology".

Also provided according to the present invention is an isolated nucleic acid molecule encoding the *C. difficile* LDH of the present invention.

For example the isolated nucleic acid molecule may comprise the nucleotide sequence of SEQ ID NO: 1. Some variation may exist within the sequence in accordance with e.g. inter-strain variation exhibited by *C. difficile*. For example, the sequence may exhibit at least 80, 85, 90, 95, 96, 97, 98, 99, or 99.5% identity with the nucleotide sequence of SEQ ID NO: 1.

10 Also provided according to the present invention is a nucleic acid vector comprising the nucleic acid molecule encoding the *C. difficile* LDH of the present invention. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the  
15 invention, the vector can be e.g. a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, or MAC. The vector may be a cloning vector or an expression vector, and may function in prokaryotic or eukaryotic cells or in both (e.g. as a shuttle vector). Appropriate cloning, expression and shuttle vectors for prokaryotic and eukaryotic hosts are described  
20 in Sambrook, J. and Russell, D., "Molecular Cloning: A Laboratory Manual", Third Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, New York, 2001.

Also provided according to the present invention is a host cell containing the vector encoding the *C. difficile* LDH of the present invention. A vector can be maintained in the  
25 host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

Also provided according to the present invention is a process for producing a polypeptide comprising the *C. difficile* LDH of the present invention, the process comprising culturing a host cell under conditions sufficient for the production of said polypeptide, and recovering said polypeptide.

5

The LDH protein or peptide sequences derived from it may be expressed and purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. For example, a nucleic acid molecule encoding the protein, or peptide sequence, is cloned into an expression vector, the expression vector introduced into a host 10 cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques.

Also provided according to the present invention is a vector encoding the *C. difficile* LDH of the present invention, or an antigenic fragment thereof, wherein the isolated nucleic acid 15 molecule is inserted into the vector in proper orientation and correct reading frame such that a polypeptide comprising the *C. difficile* LDH of the present invention, or an antigenic fragment thereof may be expressed by a cell transformed with said vector.

The isolated nucleic acid molecule as herein described may be operatively linked to a 20 promoter sequence.

Expression vectors contain *cis*-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell 25 with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a *trans*-acting factor interacting with the *cis*-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a *trans*-acting factor may be supplied by the host cell. Finally, a *trans*-acting factor can be produced from the vector itself. It should be understood, however, that in

some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

- 5      The regulatory sequences to which the nucleic acid molecules described herein can be operably linked includes promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage  $\lambda$ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.
- 10     In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.
- 15     In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory
- 20     sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook, J. and Russell, D., "Molecular Cloning: A Laboratory Manual", Third Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, New York, 2001.
- 25     The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodologies. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for 5 restriction enzyme digestion and ligation are well known to those of ordinary skill in the art. The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as 10 *Drosophila*, animal cells such as COS and CHO cells, plant cells, and human cells, such as HeLa, or HuH-7.

Also provided according to the present invention is an antibody or an antigen-binding fragment thereof specific against a *C. difficile* LDH of the present invention. For example, 15 the antibody or an antigen-binding fragment thereof may be specific against the *C. difficile* LDH consisting the sequence of SEQ ID NO: 2.

Antibodies are well known (Harlow, E. and Lane, D., "Using Antibodies - A Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor Press, New York, 1998). 20 The term "antibody" in its various grammatical forms is used herein to refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Such molecules are also referred to as "antigen binding fragments" of immunoglobulin molecules.

25

Illustrative antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')2, scFv and F(v).

A binding agent according to the present invention may not only bind to the LDH but may also neutralise or ameliorate the bacterial infection.

The antibody or antigen-binding fragment thereof specific against a *C. difficile* LDH  
5 according to the present invention may be for use in a method of treatment or diagnosis of  
the human or animal body.

Also provided according to the present invention is a method of manufacture of a  
medicament for the treatment of a *C. difficile* infection, comprising the use of an antibody  
10 or an antigen-binding fragment thereof specific against a *C. difficile* LDH according to the  
present invention.

The LDH protein or epitopes derived from the LDH protein may be used to generate  
antibodies. Epitopes of the bacterial LDH protein may be determined using standard  
15 procedures (e.g. Geysen, H.M., *et al.*, J. Immunol. Methods, 1987, 102(2):259-74, PMID:  
2443575; Geysen, H.M., *et al.*, J Mol. Recognit., 1988, 1(1):32-41, PMID: 2483922; Jung,  
G., and Beck-Sickinger, A.G., 1992, Angew. Chem. Int. Ed. Eng., 31:367-486;  
Beck-Sickinger, A.G., Jung, G., Pharm. Acta Helv. 1993;68(1):3-20; PMID: 7692453).  
Antibodies or antigen-binding fragments thereof may be prepared using established  
20 immunological techniques which are well-known to a person skilled in the art (see e.g.  
Harlow, E. and Lane, D., "Using Antibodies - A Laboratory Manual", Cold Spring Harbor  
Laboratory, Cold Spring Harbor Press, New York, 1998). Thus, for example, any suitable  
host may be injected with the protein and the blood collected to yield the desired  
polyclonal antibody after appropriate purification and/or concentration (for example by  
25 affinity chromatography using the immobilised protein as the affinity medium).  
Alternatively splenocytes or lymphocytes may be recovered from the protein-injected host  
and immortalised using for example the method of Kohler *et al.* (1976, Eur. J. Immunol.,  
6: 511), the resulting cells being segregated to obtain a single genetic line producing  
monoclonal antibodies. Antibody fragments may be produced using conventional

techniques, for example, by enzymatic digestion with pepsin or papain. Where it is desired to produce recombinant antibodies according to the invention these may be produced using, for example, the methods described in EP 171469, EP 173494, EP 194276 and EP 239400.

5

The medicament may be a vaccine. Vaccination protects against infection by priming the immune system with pathogen-derived antigen(s). Vaccination is effected by a single or repeated exposures to the pathogen-derived antigen(s) and allows antibody maturation and B cell clonal expansion without the deleterious effects of the full-blown infectious process.

- 10 The LDH protein or epitopes derived from the protein may be used within a vaccine. A vaccine comprising one or more of such epitopes may be used to immunize a person, thereby decreasing the susceptibility to *C. difficile* infection. The protein and/or epitopes may be immunogenic, or they may be administered as an immunogenic composition for example comprising an adjuvant. The vaccine may be a DNA vaccine. DNA vaccines are  
15 well established and will be known to a person skilled in the art.

Since there is evidence in bacteria such as *Enterococcus faecium* (Bugg, T.D. et al., 1999, Biochemistry, 30(43), pp10408-15, PMID: 1931965) and *Staphylococcus aureus* (Milewski, W.M. et al., 1996, Antimicrob Agents Chemother 40(1), pp166-72, PMID: 8787900) that lactate dehydrogenases play an important role in the mechanism of resistance to antibiotics such as vancomycin, the combination of an antibody or an antigen-binding fragment thereof specific against a *C. difficile* LDH according to the present invention, together with an antibiotic e.g. a glycopeptide antibiotic such as vancomycin may represent a means by which an infection due to *C. difficile* may be more successfully treated. Alternatively, the glycopeptide antibiotic may be e.g. ramoplanin or teicoplanin.  
25 The antibiotic may be metronidazole, which is sometimes used in the treatment of CDAD.

The medicament may be used for the treatment of a *C. difficile* infection, and may comprise a therapeutically effective quantity of the antibody or an antigen-binding

fragment thereof specific against a *C. difficile* LDH according to the present invention, or the same in combination with a glycopeptide antibiotic e.g. vancomycin, or an antibiotic such as metronidazole. The antibody or the antigen-binding fragment thereof may act synergistically with the antibiotic, providing an enhanced therapeutic effect, i.e. an effect  
5 greater than would be expected with treatment using the combination therapy.

The medicament may be used in a method of treatment or diagnosis of the human or animal body.

10 The medicament may be used for the treatment of a *C. difficile* infection, wherein the bacterium may be resistant to glycopeptide antibiotic treatment or antibiotic treatment.

Also provided according to the present invention is a method of manufacture of a medicament for the treatment of a *C. difficile* infection, characterised in the use of a  
15 therapeutically effective quantity of an antibiotic e.g. a glycopeptide antibiotic, and an antibody or an antigen-binding fragment thereof specific against a *C. difficile* LDH according to the present invention. The antibiotic may be a glycopeptide antibiotic such as vancomycin, ramoplanin or teicoplanin. Alternatively, the antibiotic may be metronidazole.

20

Also provided according to the present invention is a method of treatment of *C. difficile* infection, comprising the step of administering to a patient in need of same a therapeutically effective quantity of an antibiotic e.g. a glycopeptide antibiotic, and an  
25 antibody or an antigen-binding fragment thereof specific against a *C. difficile* LDH according to the present invention. The antibiotic may be a glycopeptide antibiotic such as vancomycin, ramoplanin or teicoplanin. Alternatively, the antibiotic may be metronidazole.

- Medicaments and methods of treatment according to the present invention will be readily apparent to one skilled in the art. Medicaments may be prepared using pharmaceutically acceptable carriers, diluents or excipients (Remington's: The Science and Practice of Pharmacy (1995) Mack Publishing Company, Easton, PA, USA). The medicaments and 5 methods of treatment may be effected using a pharmaceutically effective amount of the epitope or antibody/antigen-binding fragment. Appropriate dosages will be readily apparent to one skilled in the art and may be readily determined, for example by means of dose-response experiments
- 10 Also provided according to the present invention is a diagnostic test method for detecting the presence in a sample of said *C. difficile* LDH, comprising the steps of:
- 15 i) contacting said sample with an antibody or an antigen-binding fragment thereof specific against a *C. difficile* LDH according to the present invention;
- 20 ii) detecting any antibody-antigen binding reaction; and
- iii) correlating the results of detection step (ii) with the presence of said *C. difficile* LDH in said sample.

Also provided according to the present invention is a diagnostic test method for detecting the presence in a sample of antibody specific against a *C. difficile* LDH according to the present invention, comprising the steps of:

- 25 i) contacting said *C. difficile* LDH with said sample;
- ii) detecting any antibody-antigen binding reaction; and

- iii) correlating the results of detection step (ii) with the presence of antibody specific against said *C. difficile* LDH in said sample.

The sample may be from a patient, for example a serum sample or a peritoneal dialysate,  
5 although any other sample which may contain, or which might be expected to contain, anti-  
*C. difficile* antibodies may of course be used.

Also provided according to the present invention is a diagnostic test kit for performing a diagnostic test method according to the present invention. Diagnostic test kits are well  
10 known and may for example include dip-stick tests according to WO 88/08534. The test kit may include instructions for its use in a diagnostic test method according to the present invention.

Also provided according to the present invention is a pharmaceutical pack for the treatment of a *C. difficile* infection, comprising a therapeutically effective quantity of an antibiotic and an antibody or an antigen-binding fragment thereof specific against a *C. difficile* LDH according to the present invention.  
15

The antibiotic may be metronidazole, or the antibiotic may be a glycopeptide antibiotic  
20 e.g. vancomycin, ramoplanin, or teicoplanin

The infection may be due to *C. difficile*, which may be resistant to treatment by the antibiotic alone.

25 The invention will be further apparent from the following experiments which describe the isolation and characterization of *C. difficile* LDH.

### Experiments

The experiments detailed below demonstrate in immunoblotting experiments using fractionated *C. difficile* protein extracts and antisera obtained from patients infected with *C. difficile* that a protein of apparent molecular weight 36 kDa is recognised by a majority 5 of patients. Using amino acid sequencing, this protein was determined to be lactate dehydrogenase (LDH). The gene encoding the *C. difficile* LDH protein was cloned, and then subcloned into a bacterial expression vector for expression of recombinant LDH protein. Purified recombinant LDH protein was fractionated by SDS-PAGE and 2D electrophoresis and immunoblotted prior to probing with antisera obtained from patients 10 infected with *C. difficile*.

Unless stated otherwise, all procedures detailed herein were performed using standard protocols and following manufacturer's instructions where applicable. Standard protocols for various techniques including PCR, molecular cloning, manipulation and sequencing, 15 and cell culturing, are described in texts such as McPherson, M.J. *et al.* (1991, PCR: A practical approach, Oxford University Press, Oxford), Sambrook, J. and Russell, D., ("Molecular Cloning: A Laboratory Manual", Third Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, New York, 2001), Huynh and Davies (1985, "DNA Cloning Vol I - A Practical Approach", IRL Press, Oxford, Ed. D.M. Glover), Sanger, F. 20 *et al.* (1977, PNAS USA 74(12): 5463-5467), Harlow, E. and Lane, D. ("Using Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, New York, 1998), Harris, M.A. and Rae, I.F. ("General Techniques of Cell Culture", 1997, Cambridge University Press, ISBN 0521 573645).

25 Reagents and equipment useful in, amongst others, the methods detailed herein are available from the likes of Amersham ([www.amersham.co.uk](http://www.amersham.co.uk)), Boehringer Mannheim ([www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)), Clontech ([www.clontech.com](http://www.clontech.com)), Genosys ([www.genosys.com](http://www.genosys.com)), Millipore ([www.millipore.com](http://www.millipore.com)), Novagen ([www.novagen.com](http://www.novagen.com)), Perkin Elmer ([www.perkinelmer.com](http://www.perkinelmer.com)), Pharmacia ([www.pharmacia.com](http://www.pharmacia.com)), Promega

([www.promega.com](http://www.promega.com)), Qiagen ([www.qiagen.com](http://www.qiagen.com)), Sigma ([www.sigma-aldrich.com](http://www.sigma-aldrich.com)) and Stratagene ([www.stratagene.com](http://www.stratagene.com)).

- Where "PMID" reference numbers are given for publications, these are the PubMed identification numbers allocated to them by the US National Library of Medicine, from which full bibliographic information and abstract for each publication is available at [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov). This can also provide direct access to electronic copies of the complete publications, particularly in the case of e.g. PNAS, JBC and MBC publications.
- 5      The contents of each of the references discussed herein, including the references cited therein, are herein incorporated by reference in their entirety.
- 10     The contents of each of the references discussed herein, including the references cited therein, are herein incorporated by reference in their entirety.

### ***Methods***

#### ***Samples***

- 15     Serum samples and stool specimens were collected and stored at -20°C and 4°C respectively.

#### ***C. difficile Tox AB II Test***

- This kit was purchased from Tec Lab Inc., USA. 50 µl of liquid stool was added to 200  
20 µl diluent and 100 µl of the mix was added to 50 µl of conjugate in a microtitre plate and incubated for 50 minutes at 35°C, followed by 4 washes. Substrates A and B were added to the plate, mixed and incubated for 10 minutes at room temperature. Stop solution was added the plate incubated for a further 10 minutes and the O.D. measured at 450 nm.

#### ***25     Culture and identity***

The positive specimens were cultured using *C. difficile* agar base (Oxoid) with *C. difficile* selective supplement, D-cycloserine and cefoxitin (Oxoid) and grown under anaerobic conditions for 48 hours. The identities of the positive specimens were confirmed using the

enzymatic hydrolysis PRO test (Key Scientific Products, USA) and the latex agglutination test (Microscreen *C. difficile*, Microgen Bioproducts Ltd, UK).

*Antigen Preparation*

- 5     *C. difficile* NCTC 11204 was cultured under anaerobic conditions in medium containing 2% (w/v) protease peptone and 1% (w/v) yeast extract at 37°C for 48 hours. The cells were harvested by centrifugation and washed 3 times in sterile saline. The cell paste was then placed into the Bio X-presser cell disintegrator (LKB Instruments Sweden) and left at -20°C overnight prior to crushing. The samples were crushed washed and visualised by  
10 SDS-PAGE.

*Sample Visualisation and Protein Identification*

*SDS-PAGE*

- Plates were assembled according to the manufacturer's instructions and a resolving gel (25  
15 ml 30% acrylamide/bis, 14.06 ml separating gel buffer (24.22 g Tris base, made up to 100 ml with distilled water (pH 8.8), 750 µl 10% SDS, 35.2 ml distilled water, 375 µl 10% ammonium persulphate, 37.5 µl TEMED) was poured. Once set, a stacking gel (3.6 ml 30% acrylamide/bis, 7.3 ml stacking gel buffer (6.05 g Tris base made up to 100 ml with distilled water (pH 6.8), 300 µl 10% SDS, 19 ml distilled water, 300 µl 10% ammonium  
20 persulphate, 30 µl TEMED), was poured, a comb inserted and centred. The gel was left to set, the comb removed and the wells washed with distilled water. The gel was placed into the tank holder and into the tank. The samples (10 µl of *C. difficile*) were added to each well and electrophoresis buffer (18.96 g Tris base, 12 g glycine, 3 g SDS, 3 L distilled water) layered on top. The tank filled with electrophoresis buffer, the water turned on and  
25 run at a constant current of 80-100 mA for 1-2 hours.

*Protein Visualisation*

Protein bands were visualised by fixing the gels overnight at 4°C in 100 ml methanol, 20 ml glacial acetic acid followed by silver staining using the OWL Silver Staining Kit (NBS Biologicals, Huntingdon).

5

*Western blotting*

Gel holders were assembled according to the manufacture's instructions forming a sandwich as follows: Scotchbrite, 2 x filter paper, nitrocellulose/PVDF, gel, 2 x filter paper, Scotchbrite (the Scotchbrite, filter paper, and nitrocellulose/PVDF were all pre-soaked in transblotting buffer (9.07 g Tris base, 43.2 g glycine, 3 L distilled water, 750 ml methanol). The holders were slotted into the tank and run at 100 A for 45 minutes.

Sera were available from 24 patients with clinical *C. difficile* colitis and a positive toxin assay on faeces, and from 20 patients with no evidence of colitis and a negative toxin assay. The sera were added to the transblotted antigen strips and incubated with shaking at room temperature for 2 hours. Five 5 minute washes were followed by a 1 hour incubation with anti-human IgG, IgA or IgM conjugated with alkaline phosphatase. The strips were washed prior to visualisation using BCIP/NBT.

20      *Protein Sequencing*

The appropriate band was transblotted onto PVDF membrane and direct amino acid sequencing was performed using standard methodologies.

*Library Construction and Analysis of Clones*

25      *Genomic Library Construction*

*C. difficile* NCTC 11204 was grown under anaerobic conditions overnight at 37°C in 10 ml LB broth. The bacteria were harvested by centrifugation, and the pellet was washed twice in sterile saline and resuspended in 1 ml TE buffer. 1 µl lysozyme was added to the cells followed by an incubation at 37°C for 15 minutes. 20 µl of proteinase K and 50 µl

of 10% SDS was added to the mixture, which was inverted to mix and left at 55°C for 45 minutes. The mixture was pulsed in a microfuge, the supernatant was transferred to a tube containing an equal volume of phenol:chloroform:isoamylalcohol (25:25:1) and mixed by inversion for 10 minutes to precipitate protein. This was followed by centrifugation at 5 12000 x g for 10 minutes. The upper aqueous DNA-containing layer was removed and the above step repeated. The DNA was precipitated by mixing the aqueous layer with an equal volume of isopropanol and placing the mixture at room temperature for 15 minutes, followed by centrifugation at 12,000 g for 20 minutes. The pellet containing the bacterial DNA was washed in ice cold 70% ethanol to remove excess salt, and resuspended in 200 10 µl ultrapure water.

*Partial digestion of bacterial genomic DNA*

A restriction digest was set up containing *Hind* III, used according to the manufacturer's instructions, and 5 µl aliquots were collected at time intervals and deactivated by heating 15 to 65°C for 10 minutes. The DNA samples were ethanol precipitated and visualised by agarose gel electrophoresis. A fragment corresponding to 2-5 Kb was excised from the gel and cleaned up using the Geneclean protocol (Anachem, UK). The DNA was eluted in 20 µl sterile ultrapure water and stored at -20 °C.

20 *Purification of Plasmid DNA*

5 ml LB broth containing 100 µg/ml ampicillin was inoculated with *E. coli* containing the plasmid pTZ18R and grown overnight at 37°C in a shaking platform incubator. The bacterial cells were harvested by centrifugation and plasmid DNA was isolated and purified using the QIAprep Spin Miniprep Kit (QIAGen).

25

*Plasmid Digestion, Dephosphorylation and Ligation*

pTZ18R DNA was digested with *Hind* III and 5' phosphate groups were removed by adding 4 µl of 10 x alkaline phosphatase buffer (Promega) and 1 µl alkaline phosphatase (Promega) to 35 µl of sample, followed by an incubation at 37°C for 2 hours. The sample

was visualised on an agarose gel and cleaned up using the Geneclean kit, as described previously. The partially digested genomic DNA was ligated with pTZ18R in a small volume at 4°C overnight using T4 DNA ligase (Promega) according to the manufacturers instructions.

5

#### *Transformation*

Plasmid DNA was transformed by electroporation (200 ohms/25 µF 2.5 KV) into the following bacterial strains:

- 10      *E. coli* JM109,  
        *E. coli* ldh—DC1368 (lactate dehydrogenase deficient) IahA: Kanpfi,com (Gupta, S., and Clark, D.P., 1989, J. of Bacteriology, 171, p3650-3655)  
        *E. coli* W1485 (wild type).

The transformed bacterial cells were plated onto M9 media and incubated at 37°C overnight in both aerobic and anaerobic conditions.

15

#### *DNA Sequencing*

Individual clones were sequenced using a MegaBACE 1000 DNA Sequencer (Amersham Pharmacia Biotech). Plasmid DNA (100-500 ng) was added to 8 µl DYEnamic ET terminator reagent premix and 1 µl (5 µM) M13 forward (SEQ ID NO: 5) or M13 reverse 20 primer (SEQ ID NO: 6) in a total volume of 20 µl. Cycling conditions were 30 cycles of 95 °C, 20 seconds; 50 °C, 15 seconds; and 60 °C, 60 seconds. Unincorporated dye terminators were removed by ethanol precipitation and the DNA resuspended in 20 µl loading buffer. The reactions were loaded onto the DNA Sequencer using injection parameters of 2 KV for 30 seconds and electrophoresis at 6 KV for 200 minutes.

25

#### *Subcloning of ldh gene*

The ldh gene was reamplified from the partially digested DNA which had been subcloned into the pGEM-T easy vector (Promega, Southampton, UK) using the polymerase chain reaction (PCR) under the following conditions; 1 µg DNA, 25 pmol of each of L1 forward

(SEQ ID NO: 3) and L2 reverse (SEQ ID NO: 4) primers, 200  $\mu$ M dNTPs, 10 mM Tris-HCl pH 8.8, 50 mM KCl, 1.5 mM MgCl<sub>2</sub> and 5 units Taq polymerase. Cycling conditions utilised an initial denaturing step of 5 minutes at 94°C followed by 25 cycles of 94°C, 60 seconds; 55°C, 60 seconds; and 72°C, 60 seconds, followed by a final extension step of 7 minutes at 72°C, and 4°C hold. The samples were visualised by agarose gel electrophoresis. The ldh gene was subcloned into the pBAD-TOPO vector (Invitrogen) as follows; 2  $\mu$ l of the Genecleaned PCR product (above) was added to 1  $\mu$ l pBAD-TOPO vector and 1  $\mu$ l of the supplied salt solution in a final reaction volume of 5  $\mu$ l and incubated at room temperature for 5 minutes. *E. coli* TOP10-F' competent cells were transformed by heat-shock using 2  $\mu$ l of the final reaction and after incubation at 37°C for 1 hour in SOC medium, the cells were plated onto dry LB agar plates supplemented with 100  $\mu$ g/ml ampicillin, and the plates were incubated in an inverted position overnight at 37°C.

15 *Positive Clones*

Positive clones were amplified by PCR. One colony was added to a PCR master mix containing 50 pmol of each of pBAD forward (SEQ ID NO: 7) and L1 reverse primer, 200  $\mu$ M dNTPs, 10 mM Tris-HCl pH 8.8, 50 mM KCl, 1.5 mM MgCl<sub>2</sub> and 5 units Taq polymerase. Cycling conditions utilised an initial denaturing step of 5 minutes at 94°C followed by 25 cycles of 94°C, 60 seconds; 55°C, 60 seconds; and 72°C, 60 seconds, followed by a final extension step of 7 minutes at 72°C, and 4°C hold. The samples were visualised by agarose gel electrophoresis.

*Expression of recombinant LDH protein*

25 Each positive transformant was cultured with shaking in 10 ml LB supplemented with 100  $\mu$ g/ml ampicillin at 37 °C overnight. 100  $\mu$ l of the culture was used to inoculate fresh 10 ml broths the next morning which were subsequently grown at 37 °C, with shaking until an OD<sub>600</sub> of 0.5 was obtained. Protein expression was induced by the addition of 20% (w/v) L-arabinose followed by further incubation at 37°C for 4 hours. The cells were

pelleted by centrifugation at 4000 x g' for 15 minutes and resuspended in 100 µl SDS-PAGE buffer. The samples were heated to 70 °C for 5 minutes, and 5 µl fractionated on a gel and transblotted as described previously. Protein bands were detected using a 1:5000 dilution of anti-V5 epitope tag antibody, followed by an incubation with an 5 anti-mouse alkaline phosphatase conjugate and BCIP/NBT stain.

#### *Purification of Recombinant Protein*

A 50 ml culture was grown and protein expression induced as described above. Recovered cells were lysed using the Bio X-Presser cell disintegrator (LKB Instruments). The protein 10 was purified using the ProBond Purification System (Invitrogen), used according to the manufacturers instructions. The protein was eluted by either sequentially increasing the imidazole concentration using 5 ml of 50 mM, 200 mM, 350 mM and 500 mM Imidazole elution buffers consecutively and collecting 1 ml fractions or applying 5 ml of the native pH elution buffer and collecting 1 ml fractions. Fractions were analysed by SDS-PAGE 15 and Western blotting, essentially as described previously.

#### *SDS-PAGE and Western blotting using patient sera*

Fractions containing recombinant protein were run on an SDS-PAGE gel and immunoblotted using sera from 10 patients with confirmed *C. difficile* infections and 4 20 control sera.

#### *2D-gel electrophoresis and Western blotting using patient sera*

##### *Sample preparation*

*C. difficile* cells suspended in 10 mM PBS were sonicated on ice for five one minute 25 bursts. The resulting cell lysate was centrifuged at 13000 rpm for 5 minutes and 300 µl of the supernatant was precipitated in 20 ml 10 % trichloroacetic acid/20 mM DTT in cold acetone for 45 minutes. The proteins were recovered by centrifugation at 13000 rpm for 5 minutes and the resulting pellet was washed with cold acetone containing 20 mM DTT:

The centrifugation and washing step was repeated two more times, and the proteins were recovered by centrifugation as before, prior to fractionation by 2D gel electrophoresis.

*2D-gel electrophoresis*

- 5      The protein pellet was dissolved in sample rehydration solution and diluted with the same solution to an appropriate concentration for isoelectric focusing. Isoelectric focusing was performed using a Zoom®IPGRunner™System (Invitrogen Ltd, Carlsbad, CA, USA) over a non-linear pH range of 3-10 (7 cm) for a total of 1700 Vh, loading approximately 15 µg of protein on each strip. Prior to the second dimension separation the strips were  
10     equilibrated for 15 minutes in equilibration buffer containing 65 mM DTT and then in the same buffer containing 125 mM iodoacetamide for another 15 minutes.

The second dimension separation was carried out using NuPage 4-12 % Bis-TrisZoom gel (Invitrogen Ltd, Carlsbad, CA, USA) gels. The proteins were transblotted onto Invitrolon  
15     PVDF membrane (Invitrogen Ltd, Carlsbad, CA, USA) and blocked for 1 hour in 10 mM PBS containing 5% skimmed milk/0.1% Tween 20.

*Western blotting*

- To identify the position of LDH, the membrane was incubated for one hour with a  
20     polyclonal anti-LDH-horse radish peroxidase antibody conjugate (Abcam Limited, Cambridge, UK), which had been raised against LDH from rabbit muscle. The antibody was diluted (1:500) in 10 mM PBS/0.1% Tween 20 (PBS-T). After washing in PBS-T the blot was developed using SigmaFast™3,3'-diaminobenzidine tablets (DAB).

- 25     Patient antisera, which were known to be immuno-reactive to *C. difficile* proteins of 30-40 kDa (as determined by one dimensional SDS-PAGE and immunoblotting), and therefore were potentially immuno-reactive to LDH, were selected to probe the two-dimensional blots in the same way as described above for the identification of LDH. The membranes were incubated for 50 minutes in serum diluted (1:20) in PBS-T. After washing the blots

in PBS-T, primary antibodies were detected using a secondary anti-human IgG-alkaline phosphatase conjugate (Fc specific). Primary/secondary antibody complexes were detected using SigmaFast™ 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium tablets.

5     Results

*Samples*

24 of the samples tested were positive by *C. difficile* TOX A/B II test, giving a yellow (positive) reaction. Identification was confirmed by colonial and gram morphology (gram 10 positive *Bacillus* with large oval sub terminal spore on blood agar), a positive reaction to the enzymatic hydrolysis PRO test (a dark pink to red appearance) and the latex agglutination test gave visible clumps within 2 minutes indicating the presence of *C. difficile*. Whole antigen was provided from cultures of both clinical isolates and standard (National Collection of Type Cultures (NCTC) 11204, PHLS, London, UK) strains of *C. 15 difficile*.

*SDS-PAGE*

OWL silver staining of *C. difficile* whole cell extracts showed protein bands with molecular sizes between 20 and 200 kDa.

20

*Western blotting*

IgG blotting of whole cell extracts of *C. difficile* using patient and control serum samples resulted in detection of a protein of apparent molecular weight 36 kDa which had statistically significant differences between the two groups. This protein was detected in 25 21 of the 24 patient samples as opposed to 7 of the 20 control samples ( $\chi^2=12.37$ , P value 0.001). Other immunodominant antigens were apparent at 43, 55 and 70 kDa (Table 1).

**Table 1** Details of the antibody responses (IgM, IgG and IgA) against immunodominant antigens of *C. difficile*.

5	Antigen Apparent Molecular Weight (kDa)	Control (n = 20)			Colitis Patients (n = 24)		
		IgM	IgG	IgA	IgM	IgG	IgA
36	1	7	0	4	21	3	
43	2	11	0	0	17	0	
10	55	2	7	0	4	11	6
	70	2	9	0	8	13	6

*Protein Sequencing*

The first 10 amino acid residues from the 36 kDa band were obtained by N-terminal sequencing, and are shown in Table 2. This amino acid sequence was entered into the BCM Search Launcher ([www.searchlauncherbcm.tmc.edu/](http://www.searchlauncherbcm.tmc.edu/)) which returned matches showing 60% homology with ldh, as shown in Table 3.

**Table 2** N-terminal sequence analysis results of the protein sequencing

1	2	3	4	5	6	7	8	9	10
M	K	I	L	V	F	G	A	R	D
Met	Lys	Ile	Leu	Val	Phe	Gly	Ala	Arg	Asp

Table 3 Comparison of the first 10 amino acids of the identified 36 kDa protein (using BLAST)

Protein	Number of base pairs	% Identity	Function
D-LDH	30	60	Lactate dehydrogenase
D-LDH	331	60	Lactate dehydrogenase
D-LDH	331	60	Lactate dehydrogenase

*Genomic Library*

The genomic DNA was partially digested with *Hind* III to produce DNA fragments ranging from 2-5 Kbp. The partially digested DNA was ligated into pTZ18R and transformed into *E. coli*. Recombinant clones were screened for growth and sequenced. Primers derived from this were used to PCR the ldh gene from the library prepared in pGEM-T easy (Promega) and transformed into *E.coli* JM109. Recombinant clones were confirmed by PCR and selected for sequencing.

*DNA Sequencing*

Sequencing of both products revealed a open reading frame containing the ldh gene. The insert was 950 base pairs long and encoded 310 amino acids. This resulted in partial matches (29-42% homology) with 7 other LDH proteins (including *Lactobacillus* spp., *Pediococcus acidilactici*, *Leuconostoc mesenteroides* and *E. coli*).

*SDS-PAGE and Western blotting*

Recombinant LDH protein was recognised by antibodies contained within eight of the ten patient antisera. In contrast, the recombinant protein was not detected in Western blots using any of the four control sera.

### *2D gel electrophoresis and immunoblotting*

Using a commercial anti-lactate dehydrogenase antibody it was possible to identify the LDH protein on the 2D blot. Only two intense spots were visualised by the antibody, of which only one exhibited the estimated molecular weight (approximately 34 kDa) and the estimated isoelectric point (calculated to be 4.95). Of the three patient sera that were analysed, all of them contained antibodies to LDH. One patient's antibodies were nearly exclusively reactive to LDH.

### **Summary**

- 10 These experiments describe the identification of LDH as a protein which is recognised by antibodies within sera obtained from patients infected with *C. difficile*.

### **Examples**

To treat a patient infected with *C. difficile*, antibodies or antigen-binding fragments thereof specific against the bacterial LDH protein or epitopes derived from the LDH protein are administrated to the patient orally or intravenously. An appropriate dosage is readily determined using dose response assays.

A patient is treated using a therapeutically effective combination of antibody and a glycopeptide antibiotic, for example vancomycin. The glycopeptide antibiotic is administered orally, for example as a tablet or capsule. Appropriate dosages of glycopeptide antibiotics are well known to a person skilled in the art. The antibiotic is orally administered in conjunction with the antibody, for example within the same formulation, or the antibiotic is administered at approximately the same time as the administration of the antibody. Antibodies or antigen-binding fragments thereof specific against the bacterial LDH protein or epitopes derived from the LDH protein are administrated orally or intravenously. An appropriate dosage is readily determined using dose response assays.

To vaccinate a person to decrease or eliminate susceptibility to *C. difficile* infection, or stimulate a patients immune response against the bacterium, a vaccine is administered to a patient, for example suffering from CDAD or *C. difficile* colitis, who may or may not be capable of mounting an immune response to the bacterium. The vaccine comprises a bacterial extract, or recombinant LDH protein, or epitopes derived from the protein, or combinations thereof. For those patients unable to mount an immune response to the bacterium, a vaccine comprising LDH or epitopes thereof, represents a means by which the patients immune system is stimulated to mount an appropriate response. Antibody responses are determined by monitoring the levels of anti-LDH antibodies in a sample from the patient. The vaccine comprises an adjuvant to enhance or improve the immunogenicity of the vaccine components. Patients whose immune responses are weak are rechallenged such that multiple doses of the vaccine are administered over a set period of time.

*C. difficile* is detected in a patient sample by taking an e.g. blood sample from a patient, and contacting it with an antibody or an antigen-binding fragment thereof specific against *C. difficile* LDH. For example, SDS-PAGE and Western blotting using specific anti-LDH antibodies is used to determine if *C. difficile* is present within the sample - a positive reaction as determined by Western blotting, i.e. the detection of a protein corresponding to the molecular weight of LDH indicates the presence of *C. difficile* within the sample.

Antibodies specific for *C. difficile* antigens are detected in a sample taken from a patient, for example using SDS-PAGE and Western blotting. For example, recombinant bacterial LDH, antigenic fragments thereof, or a bacterial extract are fractionated by SDS-PAGE and probed with patient antisera. A positive reaction as determined by Western blotting, i.e. the detection of a protein corresponding to the molecular weight of LDH indicates the presence of anti-*C. difficile* antibodies within the patient sample.

The antibody or an antigen-binding fragment thereof specific against *C. difficile* LDH is contained within a diagnostic test kit. Similarly, a diagnostic test kit contains recombinant bacterial LDH, fragments thereof, or a bacterial extract.

- 5 The antibody or an antigen-binding fragment thereof specific against *C. difficile* LDH is contained within a pharmaceutical pack for the treatment of a *Clostridium difficile* infection. The pharmaceutical pack comprises a therapeutically effective quantity of a glycopeptide antibiotic e.g. vancomycin.

Claims

1. A *Clostridium difficile* lactate dehydrogenase comprising the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence exhibiting at least 70, 80, 90, 95, 5 96, 97, 98, 99, or 99.5% identity with the amino acid sequence of SEQ ID NO: 2.
2. An isolated nucleic acid molecule encoding the *Clostridium difficile* lactate dehydrogenase as claimed in claim 1.
- 10 3. An isolated nucleic acid molecule according to claim 2, comprising the nucleotide sequence of SEQ ID NO: 1.
4. A nucleic acid vector comprising the nucleic acid molecule of either one of claims claim 2 or 3.
- 15 5. A host cell containing the vector of claim 4.
6. A process for producing a polypeptide comprising the *Clostridium difficile* lactate dehydrogenase according to claim 1, the process comprising culturing the host cell 20 of claim 5 under conditions sufficient for the production of said polypeptide, and recovering said polypeptide.
7. A vector according to claim 4, wherein said vector is selected from the group consisting of a plasmid, a virus, and a bacteriophage.
- 25 8. A vector according to claim 7, wherein said isolated nucleic acid molecule is inserted into said vector in proper orientation and correct reading frame such that a polypeptide comprising the *Clostridium difficile* lactate dehydrogenase may be expressed by a cell transformed with said vector.

9. A vector according to claim 8, wherein said isolated nucleic acid molecule is operatively linked to a promoter sequence.
10. An antibody or an antigen-binding fragment thereof specific against a *Clostridium difficile* lactate dehydrogenase according to claim 1.
11. An antibody or an antigen-binding fragment thereof according to claim 10 for use in a method of treatment or diagnosis of the human or animal body.
- 10 12. A method of manufacture of a medicament for the treatment of a *Clostridium difficile* infection, comprising the use of an antibody or an antigen-binding fragment thereof according to claim 10.
- 15 13. A medicament, comprising a therapeutically effective quantity of an antibiotic and an antibody or an antigen-binding fragment thereof specific against a *Clostridium difficile* lactate dehydrogenase according to claim 1.
- 20 14. A medicament according to claim 13 for use in a method of treatment or diagnosis of the human or animal body.
- 15 16. A medicament according to claim 13, being for the treatment of a *Clostridium difficile* infection.
- 25 17. A method of manufacture of a medicament for the treatment of a *Clostridium difficile* infection, characterised in the use of a therapeutically effective quantity of an antibiotic and an antibody or an antigen-binding fragment thereof specific against a *Clostridium difficile* lactate dehydrogenase according to claim 1.

17. A method of treatment of *Clostridium difficile* infection, comprising the step of administering to a patient in need of same a therapeutically effective quantity of an antibiotic and an antibody or an antigen-binding fragment thereof specific against a *Clostridium difficile* lactate dehydrogenase according to claim 1.

5

18. A diagnostic test method for detecting the presence in a sample of a *Clostridium difficile* lactate dehydrogenase according to claim 1, comprising the steps of:

10 i) contacting said sample with an antibody or an antigen-binding fragment thereof specific against said *Clostridium difficile* lactate dehydrogenase;

ii) detecting any antibody-antigen binding reaction; and

15 iii) correlating the results of detection step (ii) with the presence of said *Clostridium difficile* lactate dehydrogenase in said sample.

19. A diagnostic test method for detecting the presence in a sample of antibody specific against a *Clostridium difficile* lactate dehydrogenase according to claim 1  
20 comprising the steps of:

i) contacting said sample with said *Clostridium difficile* lactate dehydrogenase;

25 ii) detecting any antibody-antigen binding reaction; and

iii) correlating the results of detection step (ii) with the presence of antibody specific against said *Clostridium difficile* lactate dehydrogenase in said sample.

20. A diagnostic test method according to either one of claims 18 or 19, the sample being a sample from a patient.
21. A diagnostic test kit for performing a diagnostic test method according to any 5 one of claims 18-20.
22. A pharmaceutical pack for the treatment of a *Clostridium difficile* infection, comprising a therapeutically effective quantity of an antibiotic and an antibody or an antigen-binding fragment thereof specific against a *Clostridium difficile* lactate dehydrogenase according to claim 1. 10
23. A medicament, method of manufacture, method of treatment, diagnostic test method, diagnostic test kit, or pharmaceutical pack according to any one of claims 12-22, said antibiotic being vancomycin, ramoplanin, teicoplanin, or metronidazole. 15
24. A medicament, method of manufacture, method of treatment, diagnostic test method, diagnostic test kit, or pharmaceutical pack according to any one of claims 12-22, said infection being due to *Clostridium difficile*.
- 20 25. A medicament, method of manufacture, method of treatment, diagnostic test method, diagnostic test kit, or pharmaceutical pack according to any one of claims 12-22, said bacterium being resistant to treatment by said antibiotic alone.

**Abstract**

The present invention discloses a *Clostridium difficile* lactate dehydrogenase comprising the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence exhibiting at least 5 70, 80, 90, 95, 96, 97, 98, 99, or 99.5% identity with the amino acid sequence of SEQ ID NO: 2. A *Clostridium difficile* lactate dehydrogenase comprising the amino acid sequence of SEQ ID NO: 2.

Also disclosed are nucleic acid sequences encoding same, vectors and host cells, antibodies against same, medicaments and methods of manufacture of a medicament for 10 the treatment of a *Clostridium difficile* infection, and diagnostic test kits and diagnostic test methods for same.

SEQUENCE LISTING

5 <110> NeuTec Pharma PLC

<120> Treatment of Infection due to Clostridium difficile

<130> MP100397

10 <160> 7

<170> PatentIn version 3.2

15 <210> 1  
<211> 975  
<212> DNA  
<213> Clostridium difficile

20 <220>  
<221> CDS  
<222> (40) .. (975)

25 <400> 1  
attaccataa taatttaata attacaggag ggtattgat atg aaa ata cta gta 54  
Met Lys Ile Leu Val  
1 5

30 ttt gga gca cgc gat tat gaa gaa cca gta ata aaa aaa tgg tct gaa 102  
Phe Gly Ala Arg Asp Tyr Glu Pro Val Ile Lys Lys Trp Ser Glu  
10 15 20

35 gaa cat aag gat gtt caa gtg gat att tat cct gaa aac atg act gaa 150  
Glu His Lys Asp Val Gln Val Asp Ile Tyr Pro Glu Asn Met Thr Glu  
25 30 35

gaa aat gta gtt aaa gct aaa ggg tat gat ggt ata tct ata caa caa 198  
Glu Asn Val Val Lys Ala Lys Gly Tyr Asp Gly Ile Ser Ile Gln Gln

	40	45	50	
	act aac tat ata gat aat cct tat att tat gaa act tta aaa gat gct			246
	Thr Asn Tyr Ile Asp Asn Pro Tyr Ile Tyr Glu Thr Leu Lys Asp Ala			
5	55	60	65	
	ggg gtt aaa gtt ata gct tca aga act gca ggg gtt gac atg ata cat			294.
	Gly Val Lys Val Ile Ala Ser Arg Thr Ala Gly Val Asp Met Ile His			
	70	75	80	85
10	ttt gat tta gtt aat gaa aat gga ctt atc gtt aca aac gtt cct got			342
	Phe Asp Leu Val Asn Glu Asn Gly Leu Ile Val Thr Asn Val Pro Ala			
	90	95	100	
15	tat tca cct aat gca ata gct gaa tta gct gtt act caa gct atg aac			390
	Tyr Ser Pro Asn Ala Ile Ala Glu Leu Ala Val Thr Gln Ala Met Asn			
	105	110	115	
20	ctt tta aga aag act cct cta gta aag aaa aaa gtc tgt gaa ggt gat			438
	Leu Leu Arg Lys Thr Pro Leu Val Lys Lys Val Cys Glu Gly Asp			
	120	125	130	
	tac cgt tgg ata gct gaa ctt ctt gga aca gaa gtt aga tct att aca			486
	Tyr Arg Trp Ile Ala Glu Leu Leu Gly Thr Glu Val Arg Ser Ile Thr			
25	135	140	145	
	gtt ggt gtt ata ggt aca gga aaa ata ggt gct act tct gca aaa tta			534
	Val Gly Val Ile Gly Thr Gly Lys Ile Gly Ala Thr Ser Ala Lys Leu			
	150	155	160	165
30	ttc aaa ggc cta gga gct aat gta att gca tat gac caa tat cca aat			582
	Phe Lys Gly Leu Gly Ala Asn Val Ile Ala Tyr Asp Gln Tyr Pro Asn			
	170	175	180	
35	agt gat tta aac gat ata tta act tac aaa gat tct tta gaa gac ctt			630
	Ser Asp Leu Asn Asp Ile Leu Thr Tyr Lys Asp Ser Leu Glu Asp Leu			
	185	190	195	
	cta aaa gaa gct gac gtt ata aca tta cat act cct tta ctt gaa gga			678

Leu Lys Glu Ala Asp Val Ile Thr Leu His Thr Pro Leu Leu Glu Gly  
200 205 210

aca aaa cat atg ata aat aaa gat act cta gct ata atg aag gat gga 726  
5 Thr Lys His Met Ile Asn Lys Asp Thr Leu Ala Ile Met Lys Asp Gly  
215 220 225

gct tac ata gta aat act gcc cgt ggt tta att gat aca ggg gat 774  
Ala Tyr Ile Val Asn Thr Ala Arg Gly Gly Leu Ile Asp Thr Gly Asp  
10 230 235 240 245

tta ata gaa gca cta gac tca gga aaa att aga gct gct gcc ctt gat 822  
Leu Ile Glu Ala Leu Asp Ser Gly Lys Ile Arg Ala Ala Ala Leu Asp  
250 255 260

15 aca ttt gaa act gaa gga ttg ttc tta aac aaa aaa atg aat cct gga 870  
Thr Phe Glu Thr Glu Gly Leu Phe Leu Asn Lys Lys Met Asn Pro Gly  
265 270 275

20 gaa tta act gac cca gaa ata aat aaa ctt ctt tct atg gaa caa gtt 918  
Glu Leu Thr Asp Pro Glu Ile Asn Lys Leu Leu Ser Met Glu Gln Val  
280 285 290

ata ttc act cat cat ctt ggt ttc act agt aca gcg att gaa aat 966  
25 Ile Phe Thr His His Leu Gly Phe Phe Thr Ser Thr Ala Ile Glu Asn  
295 300 305

ata gtt taa 975  
Ile Val

30 310

<210> 2  
<211> 311  
35 <212> PRT  
<213> Clostridium difficile  
<400> 2

Met Lys Ile Leu Val Phe Gly Ala Arg Asp Tyr Glu Glu Pro Val Ile  
1 5 10 15

5 Lys Lys Trp Ser Glu Glu His Lys Asp Val Gln Val Asp Ile Tyr Pro  
20 25 30

Glu Asn Met Thr Glu Glu Asn Val Val Lys Ala Lys Gly Tyr Asp Gly  
10 35 40 45

Ile Ser Ile Gln Gln Thr Asn Tyr Ile Asp Asn Pro Tyr Ile Tyr Glu  
15 50 55 60

Thr Leu Lys Asp Ala Gly Val Lys Val Ile Ala Ser Arg Thr Ala Gly  
65 70 75 80

20 Val Asp Met Ile His Phe Asp Leu Val Asn Glu Asn Gly Leu Ile Val  
85 90 95

25 Thr Asn Val Pro Ala Tyr Ser Pro Asn Ala Ile Ala Glu Leu Ala Val  
100 105 110

30 Thr Gln Ala Met Asn Leu Leu Arg Lys Thr Pro Leu Val Lys Lys Lys  
115 120 125

35 Val Cys Glu Gly Asp Tyr Arg Trp Ile Ala Glu Leu Leu Gly Thr Glu  
130 135 140

Val Arg Ser Ile Thr Val Gly Val Ile Gly Thr Gly Lys Ile Gly Ala  
145 150 155 160

Thr Ser Ala Lys Leu Phe Lys Gly Leu Gly Ala Asn Val Ile Ala Tyr  
165 170 175

5 Asp Gln Tyr Pro Asn Ser Asp Leu Asn Asp Ile Leu Thr Tyr Lys Asp  
180 185 190

Ser Leu Glu Asp Leu Leu Lys Glu Ala Asp Val Ile Thr Leu His Thr  
10 195 200 205

Pro Leu Leu Glu Gly Thr Lys His Met Ile Asn Lys Asp Thr Leu Ala  
15 210 215 220

Ile Met Lys Asp Gly Ala Tyr Ile Val Asn Thr Ala Arg Gly Gly Leu  
225 230 235 240

20 Ile Asp Thr Gly Asp Leu Ile Glu Ala Leu Asp Ser Gly Lys Ile Arg  
245 250 255

25 Ala Ala Ala Leu Asp Thr Phe Glu Thr Glu Gly Leu Phe Leu Asn Lys  
260 265 270

30 Lys Met Asn Pro Gly Glu Leu Thr Asp Pro Glu Ile Asn Lys Leu Leu  
275 280 285

35 Ser Met Glu Gln Val Ile Phe Thr His His Leu Gly Phe Phe Thr Ser  
290 295 300

Thr Ala Ile Glu Asn Ile Val  
305 310

<210> 3  
<211> 20  
<212> DNA  
<213> Artificial Sequence

5

<220>  
<223> PCR primer

<400> 3  
10 atgaaaatac tagtatttgg

20

<210> 4  
<211> 21  
15 <212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR primer

20

<400> 4  
ttaaaactata ttttcaatcg c

21

25 <210> 5  
<211> 17  
<212> DNA  
<213> Artificial sequence

30 <220>  
<223> PCR Primer

<400> 5  
gttttcccag tcacgac

17

35

<210> 6  
<211> 17  
<212> DNA

<213> Artificial sequence

<220>

<223> PCR Primer

5

<400> 6

cagggaaacag ctatgac

17

10 <210> 7

<211> 20

<212> DNA

<213> Artificial sequence

15 <220>

<223> PCR Primer

<400> 7

atgccatagc attttatcc

20

20

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**